TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04838132

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral transversus thoracis muscle plane and rectus sheath block with ropivacaine
Description: A linear array transducer (6-13 MHz) with a sterile cover and a 22-gauge (G) block needle (KDL™, Kindly group, Shanghai, China) will be used. Place the ultrasound probe on the longitudinal plane 1 cm outside the edge of the sternum in the fourth intercostal space, and identify the T3-T4 intercostal space under ultrasound. Use the plane technique to place a 22-gauge, 80-mm needle obliquely upwards until the needle tip is located at the plane between the internal intercostal muscles and the transverse pectoralis muscle. After general anesthesia, all subjects were injected with 0.3% ropivacaine 15ml and 10ml respectively after insertion of a needle into bilateral transverse thoracic muscle plane and rectus sheath guided by B-ultrasound.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral transversus thoracis muscle plane and rectus sheath puncture with saline
Description: A linear array transducer (6-13 MHz) with a sterile cover and a 22-gauge (G) block needle (KDL™, Kindly group, Shanghai, China) will be used. Place the ultrasound probe on the longitudinal plane 1 cm outside the edge of the sternum in the fourth intercostal space, and identify the T3-T4 intercostal space under ultrasound. Use the plane technique to place a 22-gauge, 80-mm needle obliquely upwards until the needle tip is located at the plane between the internal intercostal muscles and the transverse pectoralis muscle. After general anesthesia, all subjects were injected with 0.9% saline 15ml and 10ml respectively after insertion of a needle into bilateral transverse thoracic muscle plane and rectus sheath guided by B-ultrasound.
Study: NCT05558709

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REALSOCOG
Description: Patients will be asked to perform the REALSoCog serious game-type social cognition assessment task developed by the LMC2 laboratory (UR 7536). Their performance will be compared to those of control individuals recruited in parallel (independant clinical study: CER-U, IRB N°: 00012020-115). Participants will be asked to think about 16 social situations (6 control situations and 10 experimental situations) encountered in a virtual environment representing a city. REALSoCog can be used on a laptop computer, without any additional technical device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BCS
Description: Social-cognitive tasks from the BCS (Ehrlé et al., 2011) will also be offered to patients to test the concurrent validity of REALSoCog. This battery assesses social cognition. It includes paper-and-pencil tasks.

Intervention type: OTHER
Group type: OTHER
Intervention: Hetero-questionnaires
Description: Hetero-questionnaires assessing patients' social behavior will be transmitted to their relative or primary caregiver (Godefroy \& le GREFEX, 2008; Gury and Ehrlé, in progress of validation) in order to verify the concurrent validity of REALSoCog. These hetero-questionnaires aim to identify and quantify the presence of social skills and behaviour disorders.
Study: NCT06372392

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Universal meal coefficient utilization
Description: Usage of universal fixed meal bolus coefficients for the control of postprandial hyperglycemia compared to individualized coefficients n the users of Medtronic Minimed 780G pumps

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Universal meal coefficient utilization
Description: Usage of universal fixed meal bolus coefficients for the control of postprandial hyperglycemia compared to individualized coefficients n the users of Medtronic Minimed 780G pumps
Study: NCT06056323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0045 Drug Product
Description: Patients will be assigned to dose regimens in the order of enrollment and receive their assigned fixed dose of HB0045 via intravenous infusion, Q3W.
Study: NCT04478994

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TEPEZZA
Description: TEPEZZA is a fully human anti-IGF-1R mAb. TEPEZZA will be provided in single-dose 20 mL glass vials as a freeze-dried powder. Each vial of TEPEZZA must be reconstituted with 10 mL of water for injection. Reconstituted TEPEZZA solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration. TEPEZZA will be administered in 100 mL or 250 mL infusion bags (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will consist of normal saline (0.9% NaCl) solution and will be administered in 100 mL or 250 mL infusion bags, as would be appropriate, per weight-based dosing volumes (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses \> 1800 mg).
Study: NCT05358704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil)
Description: To evaluate the safety and preliminary efficacy of Preoperative ChemoRadiation and FOLFOXIRI To Escalate Complete Response for Rectal Cancer patients. receive the experimental combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil) and undergo laboratory tests and study procedures on specified days during the study period, complete end of study evaluations and tests, and participate in post-study follow up every three months for three to four years.
Study: NCT04934371

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: TDCS is a procedure that sends weak electrical currents between points on the scalp. Some of this current flows through the brain, and may induce temporary changes in brain activity lasting 30-60 minutes beyond the time of stimulation. TDCS is believed to be very low risk. TDCS has been applied in more than 4900 studies and hundreds of people to treat various neurological and psychiatric conditions, including depression, epilepsy, chronic pain and Parkinson's. In this study we will use tDCS to suppress symptom of tinnitus and hyperacusis.
Study: NCT04969146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic Intervention
Description: The patient and caregiver dyads will complete and return baseline questionnaires and then be randomized to Modified CBTi Dyadic Intervention. The patient and caregiver in the dyadic intervention will have 5 sessions of Modified CBTi. Upon completion of the intervention, the patient and caregiver will complete the follow up assessments at approximately 3 months and 6 months after the baseline questionnaires.
Study: NCT04934371

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TDCS
Description: Sham control will be administered to the same area as active TDCS
Study: NCT06491719

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NCR300（Allogenic Ipsc-derived Natural Killer cells ）
Description: Patients will receive iNK cells i.V. infusion at 1.0x10\^8/kg on days +14d, +21d, +28d, and +35d post-transplant.~Continuation of the infusion after +35d post-transplant is at the discretion of the physician based on the patient's benefit.
Study: NCT06361758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab+Lenvatinib
Description: Cadonilimab (AK104): 15mg/kg Q3W iv D1 + Lenvatinib: 8 mg (body weight \<60 kg) or 12mg (body weight ≥60 kg) orally QD. Eligible patients will receive AK104 plus Lenvatinib until disease progression or withdrawn ICF or death, whichever comes first.
Study: NCT04969146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Only Intervention
Description: The patient and caregiver dyads will complete and return baseline questionnaires and then be randomized to Modified CBTi Patient Only Intervention. The patient in the Patient Only Intervention will have 5 sessions of Modified CBTi. Upon completion of the intervention, the patient and caregiver will complete the follow up assessments at approximately 3 months and 6 months after the baseline questionnaires.
Study: NCT06344728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib Oral Solution
Description: Brensocatib solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib Oral Solution
Description: Brensocatib solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib Oral Tablet
Description: Brensocatib tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib Oral Tablet
Description: Brensocatib tablet
Study: NCT04973072

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One large reward treatment
Description: Participants will be awarded S$300 for reaching the PBF goal at the end of 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small wins treatment
Description: The cash rewards that participants will receive are capped by $300 and depend on which IGs they achieve and whether they maintain their progress at the end of the 12 weeks. Specifically, given the PBF goal, the Loss Target (LT) is the difference between the initial PBF measured at the first visit and the PBF goal, i.e., LT = initial PBF - PBF goal. Then, the IG1 is to achieve 25% of the LT, the IG2 is to achieve 50% of the LT, and the IG3 is to achieve 75% of the LT. Participants will earn $75 credits to their accounts on the programme website for reaching each intermediate goal. Also, when they miss IG1 and/or IG3, they can earn the previous missing $75 credits if they reach the IG2 and the LT. At the end of the 12 weeks, they will lose some or all the credits that they have accumulated if they fail to maintain the progress, and they will only receive the corresponding amount in cash
Study: NCT05044286

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT05637372

Intervention type: RADIATION
Intervention: CBCT
Description: CBCT scan
Study: NCT04890249

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational IOL Model C1V000
Description: IOL replaces the natural lens removed during cataract surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational IOL Model C2V000
Description: IOL replaces the natural lens removed during cataract surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control IOL Model ICB00
Description: IOL replaces the natural lens removed during cataract surgery.
Study: NCT05354999

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate and caffeine
Description: On experimental days subjects ingest a combination of sodium bicarbonate, caffeine and placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sodium bicarbonate and caffeine
Description: On experimental days subjects ingest a combination of sodium bicarbonate, caffeine and placebo.
Study: NCT05945368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate injection、Pertuzumab、Trastuzumab
Description: * Eribulin mesylate, 1.4 mg /m², day 1 and day 8;~* Trastuzumab, 8 mg/kg load dose in the first cycle and 6 mg/kg in each subsequent cycle on day 1;~* Pertuzumab, 840 mg load dose in the first cycle and 420 mg in each subsequent cycle on day 1; There are four cycles in 21 days
Study: NCT06516653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VasQ
Description: External support implant for the arteriovenous fistula

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arteriovenous fistula creation for dialysis vascular access
Description: End to side fistula creation in the arm for dialysis vascular access

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arteriovenous fistula creation for dialysis vascular access
Description: End to side fistula creation in the arm for dialysis vascular access
Study: NCT06530706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine 0.2mg/kg was pumped slowly after intubation, followed by 0.1mg/kg pumped until the end of the operation. In the PCIA pump, esketamine 1mg/kg was added to the sufentanil.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Same volume of normal saline was pumped slowly after intubation, followed by the same volume of NS until the end of the operation. In the PCIA pump, only sufentanil was used.
Study: NCT05635591

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous monocyte - derived DCs pulsed with EBV antigen
Description: Patients will receive approximately （5-10）x10\^6 DC vaccine via subcutaneous injections bi-weekly,totally 3-5 times.
Study: NCT06086106

Intervention type: PROCEDURE
Intervention: caudal block
Description: The caudal block involves the injection of a local anesthetic Bupivacaine dose of 0.75 to 1 ml/kg the maximum volume was 10 mL with 0.25% concentration into the caudal epidural space, targeting the sacral nerve roots. to provide a high effect and duration of analgesia
Study: NCT04859699

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 Health Education Comic Books and Videos
Description: Comic books and videos will be shared with intervention students and their parents to provide education on COVID-19 topics such as masking, social distancing and COVID-19 testing
Study: NCT04962191

Intervention type: DIAGNOSTIC_TEST
Intervention: Idylla EGFR Mutation Test
Description: This diagnostic test is performed on the BioCartis Idylla System for qualitative detection of exon mutations.
Study: NCT05373017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DANE Recovery Program
Description: Virtual visits with care coordinator to carry out an individualized recovery plan
Study: NCT05307354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tibial Nerve Mobilization
Description: The person performing tibial nerve mobilization will start mobilization by keeping the lower extremity in a horizontal position, with the patient's hip and knee in 45° flexion and ankle in neutral position. Then, in order to mobilize the tibial nerve better, the patient will bring the patient's toes to the extension position, the ankle to the dorsiflexion and eversion position, and the knee joint to the extension to provide appropriate stabilization. Finally, while the patient is in this position, mobilization will be completed by plantar flexion of the distal ankle and flexion of the toes to allow the nerve to slide further distally. This mobilization technique will be performed by an experienced physician/physiotherapist twice a week for 4 weeks, and the patients will be given 5 sets of 10 cycles with a 1-minute rest period in each set.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Foot-ankle range of motion exercises
Description: In exercise program, foot-ankle joint range of motion exercises will be given. In our study, all exercises will be explained and performed once under the supervision of a physiotherapist, and then the participants will be asked to do all exercises with 10 repetitions, 3 times a day, for four weeks, without the supervision of a physiotherapist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot-ankle range of motion exercises
Description: In exercise program, foot-ankle joint range of motion exercises will be given. In our study, all exercises will be explained and performed once under the supervision of a physiotherapist, and then the participants will be asked to do all exercises with 10 repetitions, 3 times a day, for four weeks, without the supervision of a physiotherapist.
Study: NCT05373017

Intervention type: OTHER
Group type: OTHER
Intervention: DANE Recovery Program
Description: Virtual visits with care coordinator to carry out an individualized recovery plan
Study: NCT04295525

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 400 mg mucoadhesive oral tablet
Description: AqualiefTM (Metis Healthcare s.r.l., Milano, Italy)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 400 mg mucoadhesive oral tablet
Description: AqualiefTM (Metis Healthcare s.r.l., Milano, Italy)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo mucoadhesive oral tablet
Description: placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo mucoadhesive oral tablet
Description: placebo
Study: NCT05373017

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Physical, cognitive, and psychological assessments
Study: NCT06525506

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IBI311 (20 mg)
Description: Arm 4: 10 mg/kg IBI311 on Day 1, followed by 20 mg/kg IBI311 from week 3 to week 21, Q3W.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IBI311 (3-20 mg)
Description: Arm 2: 3 mg/kg IBI311 from day 1 to week 9, Q3W, followed by 20 mg/kg IBI311 from week 12 to week 21, Q3W.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IBI311 (10 mg)
Description: Arm 3: 10 mg/kg IBI311 from day 1 to week 21, Q3W.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IBI311 (3-10mg/kg)
Description: Arm 1: 3 mg/kg IBI311 from day 1 to week 9, Q3W, followed by 10 mg/kg IBI311 from week 12 to week 21, Q3W.
Study: NCT05026749

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZM Group
Description: AZM at 20 mg/kg will be given intravenous daily for 3 days once patients are consented and enrolled into the study.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Saline will be given intravenous daily for 3 days once patients are consented and enrolled into the study.
Study: NCT05481775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 8mg qd po. Taking anlotinib daily for 2 weeks and stop for 1 week.
Study: NCT05258500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ghostly app
Description: For the Ghostly app, we include three different trainings (standard, cluster set 1, cluster set 2). The standard training consists of three sets in which twelve muscle contractions are performed with 120 seconds of rest between each set. Each set of twelve contractions will be considered as one level in the game that needs to be ended before taking rest of 120s. Subsequently, the 'Cluster set 1' training is based on the training modalities of cluster set training since evidence shows that similar results can be obtained using cluster set training compared to standard training. The Cluster sets 1 and 2 also consist of 3 sets of twelve repetitions, but with ten seconds of rest between each contraction or 30 seconds of rest after three consecutive contractions respectively. The intensity at which will be trained is 75% of maximum voluntary contraction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ghostly app
Description: For the Ghostly app, we include three different trainings (standard, cluster set 1, cluster set 2). The standard training consists of three sets in which twelve muscle contractions are performed with 120 seconds of rest between each set. Each set of twelve contractions will be considered as one level in the game that needs to be ended before taking rest of 120s. Subsequently, the 'Cluster set 1' training is based on the training modalities of cluster set training since evidence shows that similar results can be obtained using cluster set training compared to standard training. The Cluster sets 1 and 2 also consist of 3 sets of twelve repetitions, but with ten seconds of rest between each contraction or 30 seconds of rest after three consecutive contractions respectively. The intensity at which will be trained is 75% of maximum voluntary contraction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction
Description: Patients will complete four sets of 15 repetitions, with each contraction lasting three seconds. Similar to the first experimental group and control group, the training intensity will be set at 100%MVC with two minutes of rest between sets. The cuff pressure will be set at 50% of arterial occlusion pressure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Leaflet
Description: This training program will be matched with the Ghostly game in terms of repetitions, sets and inter-set rest and will be given to the patient to complete without supervision of the therapist.
Study: NCT05481775

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Docetaxel 25mg/m2 + Cisplatin 25mg/m2 QW

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Docetaxel 25mg/m2 + Cisplatin 25mg/m2 QW

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Thoracic radiotherapy was delivered using the daily image-guided intensity modulated radiation therapy (IMRT) technique. The total radiation dose was 66-68 Gy to the gross tumor in 17-22 daily fractions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Thoracic radiotherapy was delivered using the daily image-guided intensity modulated radiation therapy (IMRT) technique. The total radiation dose was 66-68 Gy to the gross tumor in 17-22 daily fractions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immunotherapy
Description: consolidation Immunotherapy (Tislelizhu 200mg iv. drip, Q3W, up to 12 months.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: consolidation Immunotherapy (Tislelizhu 200mg iv. drip, Q3W, up to 12 months.)
Study: NCT05168033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor imagery training
Description: Mentally imagine to perform rehabilitation exercises or sport-specific tasks without generating actual motor output.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classic rehabilitation
Description: Classic rehabilitation after anterior cruciate ligament reconstruction focusing on regaining mobility, stability and strength of the knee joint and return to sport.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classic rehabilitation
Description: Classic rehabilitation after anterior cruciate ligament reconstruction focusing on regaining mobility, stability and strength of the knee joint and return to sport.
Study: NCT06005740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TORL-4-500
Description: antibody drug conjugate
Study: NCT04949269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: Specified dose on specified days
Study: NCT06138041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous lidocaine infusion
Description: Lidocaine bolus of 2mg/kg after induction , and then continuous infusion with 2 mg/kg/h until the participate transfer out of postoperative anesthesia care unit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Same volume of normal saline in bolus and continuous infusion as lidocaine group.